Shares of biopharmaceutical company Incyte Corporation (NASDAQ:INCY) fell 15.2% in the pre-market session after the company released phase three trial data for a skin condition treatment ...

In trading on Tuesday, shares of Incyte Corporation (Symbol: INCY) entered into oversold territory, hitting an RSI reading of 27.5, after changing hands as low as $58.16 per share. By comparison ...

Shares of Incyte INCY were down 8.62% on Monday after the announcement of data from two late-stage studies on an oral small-molecule JAK1 inhibitor, povorcitinib, for the treatment of hidradenitis ...

Wells Fargo analyst Derek Archila maintained a Hold rating on Incyte (INCY – Research Report) yesterday and set a price target of $58.00. The company’s shares closed yesterday at $62.01.

Incyte (NASDAQ:INCY) recently announced that it had achieved positive results from both of its phase 3 studies STOP-HS1 and STOP-HS2. Both of these late-stage studies were using the company's drug ...

Shares of Incyte stock opened at $60.60 on Friday. The company has a 50-day simple moving average of $69.53 and a two-hundred day simple moving average of $70.04. Incyte has a 52-week low of $50. ...

EXCLUSIVE: Kai Caster (Yellowstone, The Baxters) has booked a leading role in the Shane Dax Taylor indie feature Halloween Store and a guest role in Amazon’s Marvel series Spider-Noir.